Plus   Neg

Smith & Nephew To Buy Swiss Optical Tracking Firm Atracsys Sàrl - Quick Facts

Medical technology company Smith & Nephew Plc (SN.L,SNN) announced Tuesday that it has agreed to acquire Atracsys Sàrl, a Swiss provider of optical tracking technology used in computer-assisted surgery. The company did not disclose the commercial terms of the deal.

The acquisition is expected to complete during the third quarter of 2019.

Atracsys' fusionTrack 500 optical tracking camera offers superior measurement speed and latency performance, and supports reduced procedure times and increased accuracy. This results in finer precision surgical tasks, such as bone cuts, compared to existing tracking technology.

Smith & Nephew said fusionTrack 500 will be a core enabling technology for its multi-asset digital surgery and robotic ecosystem, including initially in its next-generation robotics platform due for commercial release in 2020.

Atracsys' portfolio includes open platform optical navigation and robotic tracking components with applications in orthopaedics, neurosurgery, spine and dental.

Smith & Nephew said it plans for the business to continue serving these markets.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. (AAPL) unveiled a 16-inch MacBook Pro laptop with a larger screen and redesigned keyboard. It is the first major update since the MacBook Pro line was revamped three years ago. The company has moved from a 15-inch screen to a higher-resolution 16-inch screen. Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup.
Follow RTT